 studi interleukin vs lymphokine-activ killer cell treatment melanoma renal cell cancer purpos studi efficaci safeti continuous-infus interleukin regimen patient metastat melanoma renal cell cancer contribut lymphokine-activ killer cell patient lymphokine-activ killer cell twenty-thre patient renal cell carcinoma melanoma protocol object respons assess patient renal cell carcinoma melanoma patient progress diseas cycl weekli continuous-infus grade II toxic reaction fever rash anorexia gain common treat signific vivo stimul lymphokine-activ killer natur killer cell activ patient continuous-infus regimen lymphokine-activ killer cell ineffect treatment melanoma renal cell carcinoma